Guiding recombinant antivenom development by omics technologies

Laustsen, Andreas Hougaard

Published in:
New Biotechnology

Link to article, DOI:
[10.1016/j.nbt.2017.05.005](https://doi.org/10.1016/j.nbt.2017.05.005)

Publication date:
2018

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Laustsen, A. H. (2018). Guiding recombinant antivenom development by omics technologies. *New Biotechnology*, 45, 19-27. <https://doi.org/10.1016/j.nbt.2017.05.005>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Manuscript Details

Manuscript number	NBT_2017_136
Title	Guiding recombinant antivenom development by omics technologies
Article type	Review Article

Abstract

In this review, the different approaches that have been employed with the aim of developing novel antivenoms against animal envenomings are presented and discussed. Reported efforts have focused on the use of innovative immunization strategies, small molecule inhibitors against enzymatic toxins, endogenous animal proteins with toxin-neutralizing capabilities, and recombinant monoclonal antibodies. Harnessing either of these approaches, antivenom development may benefit from an in-depth understanding of venom compositions and which toxins that are essential to neutralize in an envenoming case. Focus is thus also directed towards the different omics technologies (particularly venomomics, antivenomics, and toxicovenomics) that are being used to uncover novel animal toxins, shed light on venom complexity, and provide directions for how to determine the medical relevance of individual toxins within whole venoms. Finally, techniques for assessing antivenom specificity and cross-reactivity are reviewed, with special focus on antivenomics and high-density peptide microarray technology.

Keywords	Toxinology; recombinant antivenom; toxicovenomics; antivenomics; high-density peptide microarray technology;
Corresponding Author	Andreas Laustsen
Corresponding Author's Institution	Technical University of Denmark
Order of Authors	Andreas Laustsen
Suggested reviewers	Juan J. Calvete, Manuela Pucca, Nicholas Casewell, Bruno Lomonte

Submission Files Included in this PDF

File Name [File Type]

Cover letter, New Biotechnology.docx [Cover Letter]

Laustsen. Antibody discovery guided by venom proteomics v5.doc [Manuscript File]

Highlights.docx [Highlights]

Submission Files Not Included in this PDF

File Name [File Type]

Figure 1. Toxicovenomics.png [Figure]

Figure 2. Antivenomics.png [Figure]

Figure 3, peptide microarrays.png [Figure]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

April 12th, 2017
Dr. Mike Taussig
Editor-in-Chief
New Biotechnology

Dear Dr. Mike Taussig

Thank you for your encouragement to publish in the journal. Please find attached the manuscript entitled '*Guiding recombinant antivenom development by omics technologies*', to be considered for publication as a review article in New Biotechnology.

In recent year, there has been an increased focus on how to overcome the challenge of snakebite and bring novel antivenoms to poor rural parts of the tropical world. A few reviews are already available in the field (of which I have co-authored some), however, these are focused on the individual efforts and specific toxin-neutralizing molecules, antibodies, or sera, and fail to provide an overview of the omics technologies employed to guide their development. Here, I have aimed to provide such an overview, and bring more clarity to how omics technologies interplay with toxinology and how these may be employed to guide medicinal chemistry and biotechnological efforts within antivenom development. It is my personal experience that too many research efforts have been unsuccessful, as they have attempted to develop toxin-targeting molecules without taking the complexity of venom and the often inverse relationship between toxicity and immunogenicity into account. It is my belief that an overview of how omics technologies can be harnessed in antivenom development will be useful for particularly drug development researchers (and graduate students) who are new in the field, and who need to gain an understanding of venoms and how these may be viewed and analyzed as drug targets.

I therefore hope that you will take this article into consideration.

Sincerely yours,

Dr. Andreas H. Laustsen

Guiding recombinant antivenom development by omics technologies

Andreas H. Laustsen

Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens

Lyngby, Denmark

Address for correspondence:

Dr. Andreas H. Laustsen

Postdoctoral Fellow

Department of Biotechnology and Biomedicine

Technical University of Denmark

DK-2800 Kgs. Lyngby, Denmark

[*ahola@bio.dtu.dk](mailto:ahola@bio.dtu.dk)

21 **Abstract**

22 In this review, the different approaches that have been employed with the aim of developing novel
23 antivenoms against animal envenomings are presented and discussed. Reported efforts have focused
24 on the use of innovative immunization strategies, small molecule inhibitors against enzymatic
25 toxins, endogenous animal proteins with toxin-neutralizing capabilities, and recombinant monoclonal
26 antibodies. Harnessing either of these approaches, antivenom development may benefit from an in-
27 depth understanding of venom compositions and which toxins that are essential to neutralize in an
28 envenoming case. Focus is thus also directed towards the different omics technologies (particularly
29 venomomics, antivenomics, and toxicovenomics) that are being used to uncover novel animal toxins,
30 shed light on venom complexity, and provide directions for how to determine the medical relevance
31 of individual toxins within whole venoms. Finally, techniques for assessing antivenom specificity
32 and cross-reactivity are reviewed, with special focus on antivenomics and high-density peptide
33 microarray technology.

35 **Introduction**

36 Among the tropical diseases, snakebite envenoming remains one of the most neglected, causing
37 mortality and morbidity to thousands of victims worldwide each year [1–3]. In addition,
38 envenomings by other species, particularly scorpions and spiders, also constitute a medically
39 important challenge for public health [4–7]. Modern approaches based on biotechnology and
40 medicinal chemistry are starting to see the light of day through neutralization of animal toxins by
41 monoclonal antibodies (mAbs) and small molecule inhibitors [8,9]. Yet, serum-based antivenom
42 derived from immunized animals is currently the only therapeutically effective treatment option
43 against most animal envenomings [10]. Antivenom is thus one of the few biological therapies that
44 have not yet entered the modern era of biologics, despite the presence of an overwhelmingly large
45 patient population. Although part of the explanation for the lack of innovation within antivenom
46 development may be attributed to the poor financial incentive for investment in the field, the sheer
47 complexity of animal venoms may also hold part of the answer. Not only is each venom a complex
48 mixture of toxins, but venoms are highly diverse across the known 725 venomous snake species [8],
49 2000 scorpion species, and 44,000 spider species [9]. As an example and rough estimation, it has
50 previously been suggested that between 19,000-25,000 toxins may exist in the venoms of the two
51 snake families, Elapidae and Viperidae, that contain the species of the highest medical relevance for
52 human health [8]. Although neutralization of many of these toxins and toxins from other animal
53 species may not individually be medically essential in every envenoming case [11], such numbers
54 strongly support the notion that animal venoms are among the most complex drug targets known to
55 man. In this review, novel strategies for developing modern envenoming therapies are reviewed
56 with special focus on how omics (particularly venomomics [12] and toxicovenomics [13]) technologies
57 can be employed to guide discovery of antibodies capable of neutralizing medically relevant toxins.

58

59 **Neutralization of animal toxins**

60 Animal venom toxins are proteinaceous and have evolved primarily to subdue prey, as well as to
61 deter predators. Animal toxins can exert a myriad of different pathophysiological effects in victims
62 of envenoming, including systemic neurotoxicity, haemotoxicity, myotoxicity, and cytotoxicity,
63 manifesting clinically as flaccid paralysis, involuntary muscle contraction, various coagulopathies,
64 nephrotoxicity, and local tissue damage including necrosis [14,15]. Different approaches have been
65 pursued in the attempt to combat different animal venoms and toxins, including the use of novel
66 immunization methods, small molecule inhibitors, endogenous toxin-neutralizing animal proteins,
67 and antibodies. These will be presented in the following. It is, however, beyond the scope of this
68 article to provide an exhaustive review on all the examples of individual antitoxins and novel
69 antisera that have been reported to date, as these can be found elsewhere [2,6,8,9].

70

71 ***Optimizing antisera by next generation immunization technology***

72 Two of the challenges in current antivenom production include procurement of venoms and
73 obtaining a balanced response against the medically relevant toxins within a venom [16].
74 Additionally, intraspecies venom variation is a common phenomenon [17,18], which may further
75 complicate design of effective immunization mixtures. Although differences in antibody responses
76 also occur among immunized animals for antivenoms, variation in response can to some extent be
77 controlled using standardized immunogens, such as (multi)epitope DNA strings, synthetic peptides,
78 or recombinant toxins [6]. Using such molecules also has the advantage that the immunization
79 mixture can be designed to contain only those immunogens of medical relevance to humans. A
80 prominent example of the successful use of DNA strings for immunization was reported in 2006,
81 where antisera against toxins of the two vipers, *Echis ocellatus* and *Cerastes cerastes*, were
82 successfully raised by immunizing mice in the epidermal layer of their abdominal region with a

83 multiepitope DNA immunogen using a GeneGun [19]. Using a synthetic peptide containing
84 continuous and discontinuous epitopes derived from the *Centruroides noxius* (scorpion) Cn2 toxin,
85 researchers in another study succeeded in raising efficacious antiserum in rabbits [20]. Similarly,
86 rabbits have also been immunized with a recombinant, non-toxic version (a toxoid) of the TsNTxP
87 toxin from *Tityus serrulatus* venom, which could protect rabbits against 20 LD₅₀s of whole venom
88 from this scorpion [21]. Nevertheless, despite these and many more examples of the successful use
89 of such modern immunization technologies, the final products of their use are still serum-based
90 medicines that are costly to produce and may be immunogenic to human recipients due to their
91 heterologous nature.

92

93 ***Using small molecule inhibitors against animal toxins***

94 A few dozen molecules have been reported to show inhibitory effects against various toxins from
95 spiders, scorpions, and snakes [8,9]. Common to all these small molecule inhibitors is that they
96 target enzymatically active toxins, either by mimicking the natural substrate or scavenging an
97 important co-factor for the apoenzyme. Examples of toxin-inhibiting small molecules include
98 varespladib, which effectively neutralizes phospholipase A₂ activity of many snake venoms [22],
99 batimastat and EDTA, which chelate Zn²⁺ ions and thereby inhibit metalloprotease activity [23],
100 and heparin, which may inhibit hyaluronidase activity [24–26]. However, no toxin-targeting small
101 molecule is currently in clinical use. More details and examples of small molecule inhibitors
102 (particularly from plants) is beyond the scope of this review and can be found elsewhere [27].

103

104 ***Harnessing natural toxin-neutralizing proteins from animals***

105 Non-antibody proteinaceous molecules capable of neutralizing animal toxins have not so far been
106 reported outside the field of snake venoms. However, for snake venoms the presence of protective

107 proteins has been described in a range of different animal species, including the South American
108 opossum, *Didelphis marsupialis* [28–30], snakes themselves [31–35], and ground squirrels
109 (*Spermophilus beecheyi*) [36]. Some of these factors have even shown greater toxin-neutralizing
110 capacity than commercial antivenoms, exemplified by the 97 kDa protein and the antithrotophic
111 complex derived from *Didelphis marsupialis* serum [30]. These proteins were 4 and 6 times more
112 potent than the commercially available antivenom against *Bothrops lanceolatus* venom and *B.*
113 *jararaca* venom, respectively [30]. Although such results are fascinating and may even seem
114 promising, two major obstacles are likely to prevent the use of these types of molecules from being
115 used as envenoming therapy. Firstly, the expression of non-standard protein formats is not always a
116 trivial matter. Given the molecular diversity of the different naturally occurring toxin-neutralizing
117 proteins, eventual expression/production would be resource-consuming to standardize (though not
118 necessarily in the distant future). Secondly, none of the toxin-neutralizing proteins are of human
119 origin; combined with the fact that many of the toxins are quite large (> 50 kDa) proteins, their
120 heterologous nature is likely to inflict adverse reactions in human recipients due to the likelihood of
121 high immunogenicity. Possibly, however, if a promising scaffold protein were to be developed with
122 low immunogenicity and able to be engineered easily to target a multitude of different toxin
123 families, it is conceivable that a molecular platform and discovery strategy could be employed for
124 development of non-antibody-based toxin-neutralizing proteins. Examples of such platform
125 technologies might include DARPins [37,38], Armadillo repeat proteins [39], affitins [40–42],
126 adhirons [43], anticalins [44], and various other protein scaffolds [45], although these molecular
127 formats are yet to be tested for their applicability for antitoxin development.

128

129 ***Employing monoclonal antibodies to neutralize animal toxins***

130 Various different monoclonal antibody (mAb) formats have been discovered and developed against
131 toxins from different animal species, including snakes, scorpions, spiders, and bees [8,9,46]. The
132 first use of a mAb capable of neutralizing a toxin was reported in 1982 using hybridoma technology
133 [47]. This IgG antibody targets toxin α from the Black-necked spitting cobra, *Naja nigricollis*.
134 Since then, 63 additional murine IgG mAbs targeting toxins from snakes, spiders, and scorpions
135 have been reported [8,9]. However, this number is unlikely to increase significantly, given the
136 prospects of using transgenic (humanized) animals capable of producing human IgGs more suitable
137 for human therapy and the advent of phage display technology. This is one of the most promising
138 avenues for development of novel recombinant antivenoms [48,49]. Most commonly, phage display
139 selection has been used to develop human single-chain variable fragments (scFvs) with important
140 examples including the development of Serrumab against the toxins, Ts1 and Ts2, from the
141 Brazilian yellow scorpion (*T. serrulatus*) [50,51], Afribumab targeting melittin and phospholipase
142 A₂s in Africanized bee (*Apis mellifera*) venom [46], the human scFv P2B7 capable of neutralizing
143 myotoxicity from *Bothrops jararacussu* venom [52], and ER-5 against β -neurotoxins from
144 *Centruroides* scorpion venoms [53]. Other formats, including diabodies [54,55], camelid V_HH [56–
145 60], bispecific V_HH [61], and V_HH-Fc fusions [62] have also been reported to successfully
146 neutralize a range of different toxins, particularly from scorpions and snakes. The prospect of using
147 (mixtures of) human mAbs against animal envenomings has gained increasing interest in recent
148 years. The reasons for this include the versatility of the (human) antibody scaffold, its compatibility
149 with the human immune system, the success of human antibodies in other fields [63], and the
150 demonstration that recombinant antivenoms may be produced cost-competitively by mammalian
151 cell cultivation [64,65] with future production costs of antibodies likely to decrease even further
152 [66]. Despite the existence of several feasible discovery approaches (particularly using humanized

transgenic animals, phage display, or even combined approaches), a need remains to elucidate which animal toxins to focus antivenom research efforts on.

155

156 **Using omics technologies to establish order in venom complexity**

Independent of the molecular scaffold and discovery strategy employed for developing the next generation of antivenoms against animal envenomings, it is critical to have a thorough understanding of venom complexity and which toxins to target. For this purpose, different omics technologies are increasingly being used to uncover novel animal toxins and help guide antivenom development.

To date, genomes have been reported for two snakes (King cobra, *Ophiophagus Hannah*, and Burmese python, *Python molurus bivittatus*) [67,68], three spiders (African social velvet spider, *Stegodyphus mimosarum*, Brazilian white-knee tarantula, *Acanthoscurria geniculata*, and House spider, *Parasteatoda tepidariorum*) [69,70], one scorpion (Manchurian scorpion, *Mesobuthus martensii*) [71], and the honey bee (*Apis mellifera*) [72]. In addition, a multitude of transcriptomics studies has been performed, particularly on the venom glands from snakes, scorpions, and spiders [8,9]. These have all provided important evolutionary insight into the biology of venomous animals and may be used to uncover novel toxins with unique functionalities. In general, however, correlation between mRNA transcripts and protein expression may not always be high [73], which has on several occasions shown to be the case for certain snake venoms from both the viper and elapid families [74–76]. Therefore, genomic and transcriptomic studies may benefit from combination with proteomics to establish a full overview of a venom.

The state of the art for elucidation of venom composition is based on the venomomics approach, combining venom fractionation by chromatography and gel electrophoresis with mass spectrometry (see [Figure 1](#)) [49,77,78]. These techniques can be used to quantitatively estimate

177 venom proteomes [79,80]. Venomics can be performed both by bottom-up [81] and top-down
178 approaches, with the latter having the benefit of being able to distinguish between closely related
179 toxin isoforms [82]. By mid-2015, approximately 140 snake venoms had undergone a venomics
180 analysis [8]. Since then, this number has been growing steadily with new studies on venomous
181 snakes from Asia, Africa, Australia, Europe, and Latin America [82–89]. Fewer venomics studies
182 have been performed on venoms from spiders, scorpions [9], bees, and insects, owing to the
183 amounts of venom needed for estimating quantitative venom proteomes, and the scarcity of venoms
184 from most of these rather small creatures. Therefore, most of the proteomic studies performed on
185 venoms from these smaller species are qualitative in nature and only provide a catalog of toxins
186 present in the venoms with unknown abundances.

187 Venomics provides a good descriptive overview of venom. However, to fully gain an
188 understanding of which toxins in a venom are important for an envenoming case, functional studies
189 are needed. One such approach is toxicovenomics (see [Figure 1](#)), which was introduced in 2015 in a
190 study of Black mamba (*Dendroaspis polylepis*) venom with the aim of identifying key toxins to be
191 neutralized by effective antivenom [90]. In this study, the Toxicity Score [11] was employed which
192 can be calculated for venom toxins and fractions (containing toxin mixtures) based on their
193 abundance and potency. The Toxicity Scores can be used to rank the toxins or fractions according
194 to their medical importance (typically judged by lethality in mice), although the difficulty of
195 isolating certain toxins, such as Snake Venom Metalloproteases (SVMPs) somewhat hinder its use
196 for some venoms [11]. Geographical and intraspecies variation may give rise to slightly different
197 estimates of quantitative venom proteomes, which may, in turn, affect the Toxicity Scores for toxins
198 in venom. Additionally, the presence of toxin synergism [91] in some snake venoms (such as the
199 Green mamba, *Dendroaspis angusticeps* [92]) may further obscure the identification of which toxins
200 are key neutralization targets. However, when used conservatively to select the toxins which are

201 essential to neutralize in order to abrogate overall venom toxicity, the toxicovenomics approach
202 may provide a robust roadmap for antitoxin discovery. So far only elapid snake species from the
203 *Naja*, *Dendroaspis*, and *Aipysurus* genera have been investigated by toxicovenomics [18,90,92–94].
204 However, researchers from Mexico have recently employed a similar approach for selecting which
205 toxins from Mexican scorpions to focus antibody discovery efforts on [53].

206

207 **Understanding cross-reactivity by antivenomics and high-density peptide microarray** 208 **technology**

209 In addition to employing proteomics tools to gain a more complete understanding of whole venoms
210 and which toxins to neutralize with novel antivenom components, it may be beneficial to harness
211 omics technologies to assess antivenoms and antitoxins to guide their development. A particularly
212 important feature for toxin-neutralizing components is their ability to (selectively) cross-neutralize
213 entire (sub)families of venom toxins, as this allows for a decreased number of antitoxins needed in a
214 novel antivenom. Traditionally, most studies focusing on cross-reactivity and cross-neutralization
215 have been based on ELISA, enzymatic *in vitro* assays, and *in vivo* rodent assays. However, new
216 technologies emerging within the antibody field allow for more holistic and high-throughput
217 assessments of cross-reactivity.

218 One of the main issues with assessing antibodies by ELISA is that cross-reactivity
219 often correlates poorly with cross-neutralization. As a solution to this, “antivenomics” has been
220 developed based on the same methodology as venomomics [95,96]. In the antivenomics approach,
221 whole venom is pre-incubated with beads coated with antivenom antibodies, before both bound and
222 unbound venom components are analyzed by Reversed-Phase High-Performance Liquid
223 Chromatography (RP-HPLC) and compared with the RP-HPLC chromatogram and proteomic
224 analysis of the whole venom (see [Figure 2](#)) [97]. This approach, which has so far only been used for

225 serum-based antivenoms, allows for a holistic assessment of the binding capacity of antivenoms
226 against different venom components, which may further be used to assess (potential) cross-
227 reactivity to toxins from other snake species that the antivenom was not raised against [78,96].
228 Nevertheless, the methodology should, in theory, be just as useful for assessing cross-reactivity of
229 mAbs. Antivenomic studies have been performed on antivenoms against a range of different snake
230 species from Europe, Asia, Oceania, and Latin America [87,98–104]. They are yet to be performed
231 on non-snake species, possibly owing to the scarcity of venoms from smaller venomous animals.

232 To obtain a more detailed molecular view of cross-reactivity, immunoreactivity of
233 antivenoms has also been evaluated using synthetic linear peptides derived from amino acid
234 sequences of spider, scorpion, and snake toxins [105–109]. Generally, these studies have been quite
235 meticulous and low throughput, but recently a novel high-throughput approach was introduced
236 based on high-density peptide microarray technology (see [Figure 3](#)) [110]. In this pioneering study,
237 the cross-reactivity of three different antivenoms against sub-Saharan African snake species was
238 assessed and the linear elements of epitopes for all 82 reported neurotoxins from the *Dendroaspis*
239 and *Naja* genera mapped simultaneously in one experiment. Although both the previous approaches
240 and the more recent high-throughput techniques have so far only been employed in the assessment
241 of serum-based antivenoms, their applicability to characterization of mAbs is known from other
242 fields [111,112].

243 The feasibility of assessing both monoclonal and oligoclonal antibodies using both
244 antivenomics and high-density peptide microarrays may possibly be instrumental for *in vitro*
245 assessment of novel recombinant antivenoms, to reduce cost, guide development, and reduce the
246 amount of preclinical work needed.

247

248 **Conclusion**

249 Envenomings by venomous animals are one of the therapeutic areas, where medicines based on
250 animal sera are still in use. Different approaches have been tested and reported in the pursuit of
251 developing fundamentally novel antivenoms. These approaches have involved design of novel
252 immunogens (synthetic epitope DNA strings, synthetic linear peptides, and recombinant toxins and
253 toxids), the use of small molecule inhibitors against enzymatic toxins, isolation and preclinical
254 testing of endogenous animal proteins with toxin-neutralizing capabilities, and various recombinant
255 antibody formats. Other binding proteins exist that could be harnessed, but these are yet to be
256 employed within antivenom development. The most promising approach is likely to be the use of
257 mixtures of (human or camelid) mAbs due to their versatility, high target affinity, low
258 immunogenicity, and decreasing cost of production.

259 Irrespective of the approach employed, antivenom development efforts may benefit
260 significantly by being guided by different omics technologies. Genomics and transcriptomics are
261 excellent tools for uncovering novel animal toxins and investigating venom evolution. However, the
262 state of the art remains to be venom proteomics (particularly venomics and toxicovenomics), which
263 provides a better overview of venom compositions and what toxin targets are essential to neutralize
264 in envenoming cases. Finally, the use of antivenomics and high-density peptide microarray
265 technology may be exploited to gain in-depth understanding of antivenom and antibody specificity
266 and cross-reactivity.

267

268 **Acknowledgements**

269 Thanks go to Mia Øhlenschläger for proof-reading.

270

271 **Funding**

272 This work was supported by the Novo Nordisk Foundation (NNF16OC0019248) for financial
273 support.

276 **References**

- 277 [1] Gutiérrez JM, Williams D, Fan HW, Warrell DA. Snakebite envenoming from a global
 278 perspective: Towards an integrated approach. *Toxicon* 2010;56:1223–35.
 279 doi:10.1016/j.toxicon.2009.11.020.
- 280 [2] Harrison RA, Cook DA, Renjifo C, Casewell NR, Currier RB, Wagstaff SC. Research
 281 strategies to improve snakebite treatment: Challenges and progress. *J Proteomics*
 282 2011;74:1768–80. doi:10.1016/j.jprot.2011.06.019.
- 283 [3] Harrison RA, Gutiérrez JM. Priority Actions and Progress to Substantially and Sustainably
 284 Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite. *Toxins*
 285 2016;8. doi:10.3390/toxins8120351.
- 286 [4] David Warrell, José María Gutiérrez, A. Padilla. Rabies and Envenomings: a Neglected
 287 Public Health Issue: Report of a Consultative Meeting. Geneva: World Health Organization;
 288 2007.
- 289 [5] Diaz JH. The Global Epidemiology, Syndromic Classification, Management, and Prevention
 290 of Spider Bites. *Am J Trop Med Hyg* 2004;71:239–50.
- 291 [6] Carmo AO, Chatzaki M, Horta CCR, Magalhães BF, Oliveira-Mendes BBR, Chávez-
 292 Olórtégui C, et al. Evolution of alternative methodologies of scorpion antivenoms
 293 production. *Toxicon* 2015;97:64–74. doi:10.1016/j.toxicon.2015.02.007.
- 294 [7] Fatima Laraba-Djebari, Sonia Adi-Bessalem, Djelila Hammoudi-Triki. Scorpion Venoms:
 295 Pathogenesis and Biotherapies. *Toxinology - Scorpion Venoms*, vol. 4, Dordrecht Heidelberg
 296 New York London: Springer; 2015, p. 580.
- 297 [8] Laustsen AH, Engmark M, Milbo C, Johannesen J, Lomonte B, Gutiérrez JM, et al. From
 298 Fangs to Pharmacology: The Future of Snakebite Envenoming Therapy. *Curr Pharm Des*
 299 2016;22:5270–93.
- 300 [9] Laustsen AH, Solà M, Jappe EC, Oscoz S, Lauridsen LP, Engmark M. Biotechnological
 301 Trends in Spider and Scorpion Antivenom Development. *Toxins* 2016;8:226.
 302 doi:10.3390/toxins8080226.
- 303 [10] Gutiérrez JM, León G, Lomonte B, Angulo Y. Antivenoms for snakebite envenomings.
 304 *Inflamm Allergy Drug Targets* 2011;10:369–80.
- 305 [11] Laustsen AH, Lohse B, Lomonte B, Engmark M, Gutiérrez JM. Selecting key toxins for
 306 focused development of elapid snake antivenoms and inhibitors guided by a Toxicity Score.
 307 *Toxicon* 2015;104:43–5. doi:10.1016/j.toxicon.2015.07.334.
- 308 [12] Calvete JJ. Proteomic tools against the neglected pathology of snake bite envenoming. *Expert*
 309 *Rev Proteomics* 2011;8:739–58. doi:10.1586/epr.11.61.
- 310 [13] Calvete JJ, Lomonte B. A bright future for integrative venomomics. *Toxicon* 2015;107, Part
 311 B:159–62. doi:10.1016/j.toxicon.2015.10.024.
- 312 [14] Warrell DA. Clinical toxicology of snakebite in Asia. In: Meier J, White J, editors. *Handb.*
 313 *Clin. Toxicol. Anim. Venoms Poisons*, Boca Raton: CRC Press; 1995, p. 493–594.
- 314 [15] Warrell DA. Snakebites in Central and South America: Epidemiology, clinical features, and
 315 clinical management. In: Brodie III ED, editor. *Venom. Reptil. West. Hemisphere*, Ithaca,
 316 NY: Cornell University Press; 2004, p. 709–61.
- 317 [16] Laustsen AH, Engmark M, Clouser C, Timberlake S, Vigneault F, Gutiérrez JM, et al.
 318 Exploration of immunoglobulin transcriptomes from mice immunized with three-finger

- toxins and phospholipases A2 from the Central American coral snake, *Micrurus nigrocinctus*. *PeerJ* 2017;5:e2924. doi:10.7717/peerj.2924.
- [17] Alape-Girón A, Sanz L, Escolano J, Flores-Díaz M, Madrigal M, Sasa M, et al. Snake Venomics of the Lancehead Pitviper *Bothrops asper* : Geographic, Individual, and Ontogenetic Variations. *J Proteome Res* 2008;7:3556–71. doi:10.1021/pr800332p.
- [18] Laustsen AH, Gutiérrez JM, Rasmussen AR, Engmark M, Gravlund P, Sanders KL, et al. Danger in the reef: Proteome, toxicity, and neutralization of the venom of the olive sea snake, *Aipysurus laevis*. *Toxicon* 2015;107, Part B:187–96. doi:10.1016/j.toxicon.2015.07.008.
- [19] Wagstaff SC, Laing GD, Theakston RDG, Papaspyridis C, Harrison RA. Bioinformatics and Multiepitope DNA Immunization to Design Rational Snake Antivenom. *PLoS Med* 2006;5:e209. doi:10.1371/journal.pmed.0030184.
- [20] Calderon-Aranda ES, Selisko B, York EJ, Gurrola GB, Stewart JM, Possani LD. Mapping of an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scorpion *Centruroides noxius*, using discontinuous synthetic peptides. *Eur J Biochem* 1999;264:746–55. doi:10.1046/j.1432-1327.1999.00620.x.
- [21] Guatimosim SCF, Kalapothakis E, Diniz CR, Chávez-Olórtegui C. Induction of neutralizing antibodies against *Tityus serrulatus* toxins by immunization with a recombinant nontoxic protein. *Toxicon* 2000;38:113–21. doi:10.1016/S0041-0101(99)00138-5.
- [22] Lewin M, Samuel S, Merkel J, Bickler P. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. *Toxins* 2016;8. doi:10.3390/toxins8090248.
- [23] Howes J-M, Theakston RDG, Laing GD. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. *Toxicon Off J Int Soc Toxinology* 2007;49:734–9. doi:10.1016/j.toxicon.2006.11.020.
- [24] Feng L, Gao R, Gopalakrishnakone P. Isolation and characterization of a hyaluronidase from the venom of Chinese red scorpion *Buthus martensi*. *Comp Biochem Physiol Part C Toxicol Pharmacol* 2008;148:250–7. doi:10.1016/j.cbpc.2008.06.003.
- [25] Morey SS, Kiran KM, Gadag JR. Purification and properties of hyaluronidase from *Palamneus gravimanus* (Indian black scorpion) venom. *Toxicon* 2006;47:188–95. doi:10.1016/j.toxicon.2005.10.014.
- [26] Ramanaiah, M., Parthasarathy, Pr., Venkaiah, B. Isolation and characterization of hyaluronidase from scorpion (*Heterometrus fulvipes*) venom. *Biochem Int* 1989;20:301–10.
- [27] Soares AM, Tieli FK, Marcussi S, Lourenço MV, Januário AH, Sampaio SV, et al. Medicinal plants with inhibitory properties against snake venoms. *Curr Med Chem* 2005;12:2625–41.
- [28] Trento EP, Garcia OS, Rucavado A, França SC, Batalini C, Arantes EC, et al. Inhibitory properties of the anti-bothropic complex from *Didelphis albiventris* serum on toxic and pharmacological actions of metalloproteases and myotoxins from *Bothrops asper* venom. *Biochem Pharmacol* 2001;62:1521–9.
- [29] Neves-Ferreira AGC, Perales J, Fox JW, Shannon JD, Makino DL, Garratt RC, et al. Structural and functional analyses of DM43, a snake venom metalloproteinase inhibitor from *Didelphis marsupialis* serum. *J Biol Chem* 2002;277:13129–37. doi:10.1074/jbc.M200589200.
- [30] Neves-Ferreira AG, Perales J, Ovadia M, Moussatché H, Domont GB. Inhibitory properties of the antibothropic complex from the South American opossum (*Didelphis marsupialis*) serum. *Toxicon Off J Int Soc Toxinology* 1997;35:849–63.

- 365 [31] Borkow G, Gutierrez JM, Ovadia M. A potent antihemorrhagin in the serum of the non-
366 poisonous water snake *Natrix tessellata*: isolation, characterization and mechanism of
367 neutralization. *Biochim Biophys Acta* 1994;1201:482–90.
- 368 [32] Lizano S, Lomonte B, Fox JW, Gutiérrez JM. Biochemical characterization and
369 pharmacological properties of a phospholipase A2 myotoxin inhibitor from the plasma of the
370 snake *Bothrops asper*. *Biochem J* 1997;326 (Pt 3):853–9.
- 371 [33] Borkow G, Gutierrez JM, Ovadia M. Isolation, characterization and mode of neutralization of
372 a potent antihemorrhagic factor from the serum of the snake *Bothrops asper*. *Biochim*
373 *Biophys Acta* 1995;1245:232–8.
- 374 [34] Lomonte B, Cerdas L, Gené JA, Gutiérrez JM. Neutralization of local effects of the
375 terciopelo (*Bothrops asper*) venom by blood serum of the colubrid snake *Clelia clelia*.
376 *Toxicon Off J Int Soc Toxinology* 1982;20:571–9.
- 377 [35] Thwin MM, Gopalakrishnakone P. Snake envenomation and protective natural endogenous
378 proteins: a mini review of the recent developments (1991-1997). *Toxicon Off J Int Soc*
379 *Toxinology* 1998;36:1471–82.
- 380 [36] Biardi JE, Coss RG, Smith DG. California ground squirrel (*Spermophilus beecheyi*) blood
381 sera inhibits crotalid venom proteolytic activity. *Toxicon Off J Int Soc Toxinology*
382 2000;38:713–21.
- 383 [37] Stumpp MT, Binz HK, Amstutz P. DARPinS: a new generation of protein therapeutics. *Drug*
384 *Discov Today* 2008;13:695–701. doi:10.1016/j.drudis.2008.04.013.
- 385 [38] Rasool M, Malik A, Hussain M, Haq KA, Butt K, Basit A, et al. DARPinS Bioengineering
386 and its Theranostic Approaches: Emerging Trends in Protein Engineering. *Curr Pharm Des*
387 2016.
- 388 [39] Varadamsetty G, Tremmel D, Hansen S, Parmeggiani F, Plückthun A. Designed Armadillo
389 repeat proteins: library generation, characterization and selection of peptide binders with high
390 specificity. *J Mol Biol* 2012;424:68–87. doi:10.1016/j.jmb.2012.08.029.
- 391 [40] Béhar G, Renodon-Cornière A, Mouratou B, Pecorari F. Affitins as robust tailored reagents
392 for affinity chromatography purification of antibodies and non-immunoglobulin proteins. *J*
393 *Chromatogr A* 2016;1441:44–51. doi:10.1016/j.chroma.2016.02.068.
- 394 [41] Pacheco S, Béhar G, Maillason M, Mouratou B, Pecorari F. Affinity transfer to the archaeal
395 extremophilic Sac7d protein by insertion of a CDR. *Protein Eng Des Sel PEDS* 2014;27:431–
396 8. doi:10.1093/protein/gzu042.
- 397 [42] Correa A, Pacheco S, Mechaly AE, Obal G, Béhar G, Mouratou B, et al. Potent and Specific
398 Inhibition of Glycosidases by Small Artificial Binding Proteins (Affitins). *PLoS ONE*
399 2014;9. doi:10.1371/journal.pone.0097438.
- 400 [43] Tiede C, Tang AAS, Deacon SE, Mandal U, Nettleship JE, Owen RL, et al. Adhiron: a stable
401 and versatile peptide display scaffold for molecular recognition applications. *Protein Eng Des*
402 *Sel PEDS* 2014;27:145–55. doi:10.1093/protein/gzu007.
- 403 [44] Schiefner A, Skerra A. The menagerie of human lipocalins: a natural protein scaffold for
404 molecular recognition of physiological compounds. *Acc Chem Res* 2015;48:976–85.
405 doi:10.1021/ar5003973.
- 406 [45] Simeon R, Chen Z. In vitro-engineered non-antibody protein therapeutics. *Protein Cell* 2017.
407 doi:10.1007/s13238-017-0386-6.
- 408 [46] Pessenda G, Silva LC, Campos LB, Pacello EM, Pucca MB, Martinez EZ, et al. Human scFv
409 antibodies (Afrimumabs) against Africanized bee venom: Advances in melittin recognition.
410 *Toxicon* 2016;112:59–67. doi:10.1016/j.toxicon.2016.01.062.

- [47] Boulain JC, Ménez A, Couderc J, Faure G, Liacopoulos P, Fromageot P. Neutralizing monoclonal antibody specific for *Naja nigricollis* toxin alpha: preparation, characterization, and localization of the antigenic binding site. *Biochemistry (Mosc)* 1982;21:2910–5.
- [48] Roncolato EC, Campos LB, Pessenda G, Costa e Silva L, Furtado GP, Barbosa JE. Phage display as a novel promising antivenom therapy: A review. *Toxicon* 2015;93:79–84. doi:10.1016/j.toxicon.2014.11.001.
- [49] Laustsen AH. Recombinant antivenoms. 1st ed. Copenhagen, Denmark: University of Copenhagen; 2016.
- [50] Pucca MB, Zoccal KF, Roncolato EC, Bertolini TB, Campos LB, Cologna CT, et al. Serrumab: A human monoclonal antibody that counters the biochemical and immunological effects of *Tityus serrulatus* venom. *J Immunotoxicol* 2012;9:173–83. doi:10.3109/1547691X.2011.649220.
- [51] Pucca MB, Cerni FA, Peigneur S, Arantes EC, Tytgat J, Barbosa JE. Serrumab: A novel human single chain-fragment antibody with multiple scorpion toxin-neutralizing capacities. *J Immunotoxicol* 2014;11:133–40. doi:10.3109/1547691X.2013.809175.
- [52] Roncolato EC, Pucca MB, Funayama JC, Bertolini TB, Campos LB, Barbosa JE. Human antibody fragments specific for *Bothrops jararacussu* venom reduce the toxicity of other *Bothrops* sp. venoms. *J Immunotoxicol* 2013;10:160–8. doi:10.3109/1547691X.2012.703253.
- [53] Rodríguez-Rodríguez ER, Olamendi-Portugal T, Serrano-Posada H, Arredondo-López JN, Gómez-Ramírez I, Fernández-Taboada G, et al. Broadening the neutralizing capacity of a family of antibody fragments against different toxins from Mexican scorpions. *Toxicon* 2016;119:52–63. doi:10.1016/j.toxicon.2016.05.011.
- [54] Rodríguez-Rodríguez ER, Ledezma-Candanoza LM, Contreras-Ferrat LG, Olamendi-Portugal T, Possani LD, Becerril B, et al. A Single Mutation in Framework 2 of the Heavy Variable Domain Improves the Properties of a Diabody and a Related Single-Chain Antibody. *J Mol Biol* 2012;423:337–50. doi:10.1016/j.jmb.2012.07.007.
- [55] di Tommaso A, Juste MO, Martin-Eauclaire M-F, Dimier-Poisson I, Billiald P, Aubrey N. Diabody Mixture Providing Full Protection against Experimental Scorpion Envenoming with Crude *Androctonus australis* Venom. *J Biol Chem* 2012;287:14149–56. doi:10.1074/jbc.M112.348912.
- [56] Abderrazek RB, Hmila I, Vincke C, Benlasfar Z, Pellis M, Dabbek H, et al. Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom. *Biochem J* 2009;424:263–72. doi:10.1042/BJ20090697.
- [57] Hmila I, Abdallah R BA-B, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, et al. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. *Mol Immunol* 2008;45:3847–56. doi:10.1016/j.molimm.2008.04.011.
- [58] Hmila I, Cosyns B, Tounsi H, Roosens B, Caveliers V, Abderrazek RB, et al. Pre-clinical studies of toxin-specific Nanobodies: Evidence of in vivo efficacy to prevent fatal disturbances provoked by scorpion envenoming. *Toxicol Appl Pharmacol* 2012;264:222–31. doi:10.1016/j.taap.2012.07.033.
- [59] Stewart CS, MacKenzie CR, Hall JC. Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development. *Toxicon Off J Int Soc Toxinology* 2007;49:699–709. doi:10.1016/j.toxicon.2006.11.023.
- [60] Chavanayarn C, Thanongsaksrikul J, Thueng-in K, Bangphoomi K, Sookrung N, Chaicumpa W. Humanized-Single Domain Antibodies (VH/VHH) that Bound Specifically to *Naja*

- kaouthia Phospholipase A2 and Neutralized the Enzymatic Activity. *Toxins* 2012;4:554–67. doi:10.3390/toxins4070554.
- [61] Hmila I, Saerens D, Abderrazek RB, Vincke C, Abidi N, Benlasfar Z, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. *FASEB J* 2010;24:3479–89. doi:10.1096/fj.09-148213.
- [62] Richard G, Meyers AJ, McLean MD, Arbabi-Ghahroudi M, MacKenzie R, Hall JC. In Vivo Neutralization of α -Cobratoxin with High-Affinity Llama Single-Domain Antibodies (VHHs) and a VHH-Fc Antibody. *PLoS ONE* 2013;8:e69495. doi:10.1371/journal.pone.0069495.
- [63] Ringel M, Tollman P, Hersch G, Schulze U. Does size matter in R&D productivity? If not, what does? *Nat Rev Drug Discov* 2013;12:901–2. doi:10.1038/nrd4164.
- [64] Laustsen AH, Johansen KH, Engmark M, Andersen MR. Snakebites: costing recombinant antivenoms. *Nature* 2016;538:41. doi:10.1038/538041e.
- [65] Laustsen AH, Johansen KH, Engmark M, Andersen MR. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? *PLoS Negl Trop Dis* 2017;11:e0005361. doi:10.1371/journal.pntd.0005361.
- [66] Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. *Biotechnol Prog* 2007;23:995–1008. doi:10.1021/bp070117s.
- [67] Vonk FJ, Casewell NR, Henkel CV, Heimberg AM, Jansen HJ, McCleary RJR, et al. The king cobra genome reveals dynamic gene evolution and adaptation in the snake venom system. *Proc Natl Acad Sci* 2013;110:20651–6. doi:10.1073/pnas.1314702110.
- [68] Castoe TA, Koning APJ de, Hall KT, Card DC, Schield DR, Fujita MK, et al. The Burmese python genome reveals the molecular basis for extreme adaptation in snakes. *Proc Natl Acad Sci* 2013;110:20645–50. doi:10.1073/pnas.1314475110.
- [69] Sanggaard KW, Bechsgaard JS, Fang X, Duan J, Dyrlynd TF, Gupta V, et al. Spider genomes provide insight into composition and evolution of venom and silk. *Nat Commun* 2014;5. doi:10.1038/ncomms4765.
- [70] Gendreau KL, Haney RA, Schwager EE, Wierschin T, Stanke M, Richards S, et al. House spider genome uncovers evolutionary shifts in the diversity and expression of black widow venom proteins associated with extreme toxicity. *BMC Genomics* 2017;18:178. doi:10.1186/s12864-017-3551-7.
- [71] Cao Z, Yu Y, Wu Y, Hao P, Di Z, He Y, et al. The genome of *Mesobuthus martensii* reveals a unique adaptation model of arthropods. *Nat Commun* 2013;4:2602. doi:10.1038/ncomms3602.
- [72] Beye M, Gattermeier I, Hasselmann M, Gempe T, Schioett M, Baines JF, et al. Exceptionally high levels of recombination across the honey bee genome. *Genome Res* 2006;16:1339–44. doi:10.1101/gr.5680406.
- [73] Haider S, Pal R. Integrated Analysis of Transcriptomic and Proteomic Data. *Curr Genomics* 2013;14:91–110. doi:10.2174/1389202911314020003.
- [74] Durban J, Juárez P, Angulo Y, Lomonte B, Flores-Díaz M, Alape-Girón A, et al. Profiling the venom gland transcriptomes of Costa Rican snakes by 454 pyrosequencing. *BMC Genomics* 2011;12:259. doi:10.1186/1471-2164-12-259.
- [75] Tan CH, Tan KY, Fung SY, Tan NH. Venom-gland transcriptome and venom proteome of the Malaysian king cobra (*Ophiophagus hannah*). *BMC Genomics* 2015;16:687. doi:10.1186/s12864-015-1828-2.
- [76] Tan KY, Tan CH, Chanhom L, Tan NH. Comparative venom gland transcriptomics of *Naja kaouthia* (monocled cobra) from Malaysia and Thailand: elucidating geographical venom variation and insights into sequence novelty. *PeerJ* 2017;5:e3142. doi:10.7717/peerj.3142.

- 506 [77] Calvete JJ. Next-generation snake venomomics: protein-locus resolution through venom
507 proteome decomplexation. *Expert Rev Proteomics* 2014;11:315–29.
508 doi:10.1586/14789450.2014.900447.
- 509 [78] Calvete JJ. Snake venomomics: From the inventory of toxins to biology. *Toxicon* 2013;75:44–
510 62. doi:10.1016/j.toxicon.2013.03.020.
- 511 [79] Gibbs HL, Sanz L, Calvete JJ. Snake population venomomics: proteomics-based analyses of
512 individual variation reveals significant gene regulation effects on venom protein expression
513 in *Sistrurus rattlesnakes*. *J Mol Evol* 2009;68:113–25. doi:10.1007/s00239-008-9186-1.
- 514 [80] Gutiérrez JM, Lomonte B, León G, Alape-Girón A, Flores-Díaz M, Sanz L, et al. Snake
515 venomomics and antivenomics: Proteomic tools in the design and control of antivenoms for the
516 treatment of snakebite envenoming. *J Proteomics* 2009;72:165–82.
517 doi:10.1016/j.jprot.2009.01.008.
- 518 [81] Warrell DA, Gutiérrez JM, Calvete JJ, Williams D. New approaches & technologies of
519 venomomics to meet the challenge of human envenoming by snakebites in India. *Indian J Med*
520 *Res* 2013;138:38–59.
- 521 [82] Petras D, Heiss P, Harrison RA, Süßmuth RD, Calvete JJ. Top-down venomomics of the East
522 African green mamba, *Dendroaspis angusticeps*, and the black mamba, *Dendroaspis*
523 *polylepis*, highlight the complexity of their toxin arsenals. *J Proteomics* 2016;146:148–64.
524 doi:10.1016/j.jprot.2016.06.018.
- 525 [83] Tan CH, Tan KY, Yap MKK, Tan NH. Venomomics of *Tropidolaemus wagleri*, the sexually
526 dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal. *Sci Rep*
527 2017;7:43237. doi:10.1038/srep43237.
- 528 [84] Latinović Z, Leonardi A, Šribar J, Sajevec T, Žužek MC, Frangež R, et al. Venomomics of
529 *Vipera berus berus* to explain differences in pathology elicited by *Vipera ammodytes*
530 *ammodytes* envenomation: Therapeutic implications. *J Proteomics* 2016;146:34–47.
531 doi:10.1016/j.jprot.2016.06.020.
- 532 [85] Tan NH, Wong KY, Tan CH. Venomomics of *Naja sputatrix*, the Javan spitting cobra: A short
533 neurotoxin-driven venom needing improved antivenom neutralization. *J Proteomics*
534 2017;157:18–32. doi:10.1016/j.jprot.2017.01.018.
- 535 [86] Tang ELH, Tan CH, Fung SY, Tan NH. Venomomics of *Calloselasma rhodostoma*, the Malayan
536 pit viper: A complex toxin arsenal unraveled. *J Proteomics* 2016;148:44–56.
537 doi:10.1016/j.jprot.2016.07.006.
- 538 [87] Gay C, Sanz L, Calvete JJ, Pla D. Snake Venomomics and Antivenomics of *Bothrops diporus*, a
539 Medically Important Pitviper in Northeastern Argentina. *Toxins* 2015;8.
540 doi:10.3390/toxins8010009.
- 541 [88] Tan CH, Fung SY, Yap MKK, Leong PK, Liew JL, Tan NH. Unveiling the elusive and
542 exotic: Venomomics of the Malayan blue coral snake (*Calliophis bivirgata flaviceps*). *J*
543 *Proteomics* 2016;132:1–12. doi:10.1016/j.jprot.2015.11.014.
- 544 [89] Reeks T, Lavergne V, Sunagar K, Jones A, Undheim E, Dunstan N, et al. Deep venomomics of
545 the *Pseudonaja* genus reveals inter- and intra-specific variation. *J Proteomics* 2016;133:20–
546 32. doi:10.1016/j.jprot.2015.11.019.
- 547 [90] Laustsen AH, Lomonte B, Lohse B, Fernández J, Gutiérrez JM. Unveiling the nature of black
548 mamba (*Dendroaspis polylepis*) venom through venomomics and antivenom immunoprofiling:
549 Identification of key toxin targets for antivenom development. *J Proteomics* 2015;119:126–
550 42. doi:10.1016/j.jprot.2015.02.002.
- 551 [91] Laustsen AH. Toxin synergism in snake venoms. *Toxin Rev* 2016;35:165–70.
552 doi:10.1080/15569543.2016.1220397.

- 553 [92] Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Toxicovenomics and antivenom
554 profiling of the Eastern green mamba snake (*Dendroaspis angusticeps*). *J Proteomics*
555 2016;136:248–61. doi:10.1016/j.jprot.2016.02.003.
- 556 [93] Lauridsen LP, Laustsen AH, Lomonte B, Gutiérrez JM. Exploring the venom of the forest
557 cobra snake: Toxicovenomics and antivenom profiling of *Naja melanoleuca*. *J Proteomics*
558 2016;150:98–108. doi:10.1016/j.jprot.2016.08.024.
- 559 [94] Laustsen AH, Gutiérrez JM, Lohse B, Rasmussen AR, Fernández J, Milbo C, et al. Snake
560 venomomics of monocled cobra (*Naja kaouthia*) and investigation of human IgG response
561 against venom toxins. *Toxicon* 2015;99:23–35. doi:10.1016/j.toxicon.2015.03.001.
- 562 [95] Calvete JJ. Antivenomics and venom phenotyping: A marriage of convenience to address the
563 performance and range of clinical use of antivenoms. *Toxicon* 2010;56:1284–91.
564 doi:10.1016/j.toxicon.2009.12.015.
- 565 [96] Gutiérrez JM, Lomonte B, Sanz L, Calvete JJ, Pla D. Immunological profile of antivenoms:
566 Preclinical analysis of the efficacy of a polyspecific antivenom through antivenomics and
567 neutralization assays. *J Proteomics* 2014;105:340–50. doi:10.1016/j.jprot.2014.02.021.
- 568 [97] Calvete JJ, Sanz L, Angulo Y, Lomonte B, Gutiérrez JM. Venoms, venomomics, antivenomics.
569 *FEBS Lett* 2009;583:1736–43. doi:10.1016/j.febslet.2009.03.029.
- 570 [98] Calvete JJ, Cid P, Sanz L, Segura álvaro, Villalta M, Herrera M, et al. Antivenomic
571 Assessment of the Immunological Reactivity of EchITAb-Plus-ICP, an Antivenom for the
572 Treatment of Snakebite Envenoming in Sub-Saharan Africa. *Am J Trop Med Hyg*
573 2010;82:1194–201. doi:10.4269/ajtmh.2010.09-0733.
- 574 [99] Xu N, Zhao H-Y, Yin Y, Shen S-S, Shan L-L, Chen C-X, et al. Combined venomomics,
575 antivenomics and venom gland transcriptome analysis of the monocled cobra (*Naja*
576 *kaouthia*) from China. *J Proteomics* 2017. doi:10.1016/j.jprot.2017.02.018.
- 577 [100] Calvete JJ, Arias AS, Rodríguez Y, Quesada-Bernat S, Sánchez LV, Chippaux JP, et al.
578 Preclinical evaluation of three polyspecific antivenoms against the venom of *Echis ocellatus*:
579 Neutralization of toxic activities and antivenomics. *Toxicon Off J Int Soc Toxinology*
580 2016;119:280–8. doi:10.1016/j.toxicon.2016.06.022.
- 581 [101] Goncalves-Machado L. Combined venomomics, venom gland transcriptomics, bioactivities, and
582 antivenomics of two *Bothrops jararaca* populations from geographic isolated regions within
583 the Brazilian Atlantic rainforest. *J Proteomics* 2016;135:73–89.
584 doi:10.1016/j.jprot.2015.04.029.
- 585 [102] Pla D, Bande BW, Welton RE, Paiva OK, Sanz L, Segura Á, et al. Proteomics and
586 antivenomics of Papuan black snake (*Pseudechis papuanus*) venom with analysis of its
587 toxicological profile and the preclinical efficacy of Australian antivenoms. *J Proteomics*
588 2017;150:201–15. doi:10.1016/j.jprot.2016.09.007.
- 589 [103] Pla D, Calvete JJ, Elosua C, Paniagua J. Antivenomics of a European viper antivenom.
590 *Toxicon* 2016;119:371. doi:10.1016/j.toxicon.2016.06.025.
- 591 [104] Pla D, Calvete JJ, Elosua C, Paniagua J. Antivenomics of a sub-saharan Africa antivenom
592 antivipmyn Africa. *Toxicon* 2016;119:371–2. doi:10.1016/j.toxicon.2016.06.026.
- 593 [105] De-Simone SG, Napoleão-Pego P, Teixeira-Pinto LAL, Santos JDL, De-Simone TS,
594 Melgarejo AR, et al. Linear B-cell epitopes in BthTX-I, BthTX-II and BthA-1,
595 phospholipase A2's from *Bothrops jararacussu* snake venom, recognized by therapeutically
596 neutralizing commercial horse antivenom. *Toxicon* 2013;72:90–101.
597 doi:10.1016/j.toxicon.2013.06.004.
- 598 [106] Lomonte B. Identification of linear B-cell epitopes on myotoxin II, a Lys49 phospholipase
599 A2 homologue from *Bothrops asper* snake venom. *Toxicon* 2012;60:782–90.
600 doi:10.1016/j.toxicon.2012.05.028.

601 [107] Castro KL, Duarte CG, Ramos HR, Machado de Avila RA, Schneider FS, Oliveira D, et al.
602 Identification and characterization of B-cell epitopes of 3FTx and PLA2 toxins from
603 *Micrurus corallinus* snake venom. *Toxicon* 2015;93:51–60.
604 doi:10.1016/j.toxicon.2014.10.015.

605 [108] Maria WS, Velarde DT, Alvarenga LM, Nguyen C, Villard S, Granier C, et al. Localization
606 of epitopes in the toxins of *Tityus serrulatus* scorpions and neutralizing potential of
607 therapeutic antivenoms. *Toxicon* 2005;46:210–7. doi:10.1016/j.toxicon.2005.03.024.

608 [109] Ramada JS, Becker-Finco A, Minozzo JC, Felicori LF, Machado de Avila RA, Molina F, et
609 al. Synthetic peptides for in vitro evaluation of the neutralizing potency of *Loxosceles*
610 antivenoms. *Toxicon* 2013;73:47–55. doi:10.1016/j.toxicon.2013.07.007.

611 [110] Engmark M, Andersen MR, Laustsen AH, Patel J, Sullivan E, Masi F de, et al. High-
612 throughput immuno-profiling of mamba (*Dendroaspis*) venom toxin epitopes using high-
613 density peptide microarrays. *Sci Rep* 2016;6:36629. doi:10.1038/srep36629.

614 [111] Halperin RF, Stafford P, Johnston SA. Exploring Antibody Recognition of Sequence Space
615 through Random-Sequence Peptide Microarrays. *Mol Cell Proteomics MCP* 2011;10.
616 doi:10.1074/mcp.M110.000786.

617 [112] Price JV, Tangsombatvisit S, Xu G, Levy D, Baechler EC, Gozani O, et al. “On silico”
618 peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-
619 protein interactions. *Nat Med* 2012;18:1434–40. doi:10.1038/nm.2913.

620

622 **Figure legends**

623

624 **Figure 1.** Schematic overview of venomomics and toxicovenomics. Following the venomomics approach,
625 venoms are fractionated by HPLC and gel electrophoresis, and the different fractions are
626 enzymatically digested and analyzed by MALDI-TOF-TOF and bioinformatics for identification of
627 toxins. Using chromatographic data and SDS-PAGE densitometry, it is possible to quantitatively
628 estimate the venom proteome. Toxicovenomics builds upon venomomics and includes in vivo toxicity
629 data, which can be used to obtain an overview of venoms as pharmacological targets for antitoxin
630 development and determine which toxins are essential to neutralize with antivenom in an
631 envenoming case.

632

633 **Figure 2.** Schematic overview of the antivenomics approach. **A)** First venom is passed through a
634 column containing resins that are coated with antivenom. Unbound toxins are analyzed by
635 Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). **B)** Bound venom toxins
636 are then eluted and likewise analyzed by RP-HPLC. **C)** Combined with the chromatogram and a
637 proteomic analysis of the whole venom, the two analyses provide an overview of which venom
638 toxins are readily recognized and bound by a given antivenom, and which toxins are not.

639

640 **Figure 3.** Schematic overview of how high-density peptide microarrays are designed and used for
641 the study of epitope-paratope interactions between antivenoms and animal venom toxins.

642

Highlights

- nvenoming by venomous animals remain a major public health challenge in the tropics
- Biotechnological approaches are being harnessed for development of novel antivenoms
- Genomics and transcriptomics are good for uncovering novel venom toxins
- Venom proteomics is useful for identifying key toxins for neutralization by novel antivenoms
- High-density peptide microarray technology is emerging as a valuable tool in antivenom research